All posts

Cineplex stock price target lowered at Scotia

Owing to upcoming financial obligations, Scotia analyst Maher Yaghi has lowered his price target on Cineplex (Cineplex Stock Quote, Chart, News, Analysts, Financials TSX:CGX).

As reported by the Globe and Mail, Yaghi February 1 lowered his target on CGX from $11.75 to $11.00 while maintaining his “Sector Perform” rating on the stock.

The analyst explained his reasoning in a note to clients today.

“As a result of a general slowdown in box office attendance due to a pushed out movie release schedule as well as accounting dynamics related to the sale of P1AG, we are updating our estimates for Q4 as well as slightly adjusting some estimates for 2024,” he wrote. “Overall FCF generation in 2024 is still expected to be healthy, but the market remains focused on upcoming debt maturities which, until the company is able to put it behind, the stock will likely remain range bound.”

On February 8, Cineplex will report its Q4 and fiscal 2023 results. On January 11, the company reported that December box office levels were back up to 68 per cent of pre-pandemic levels.

“It’s been a record year for Cineplex’s international programming. As part of our content broadening strategy, international content helped alleviate short-term supply challenges resulting from the now-resolved actors’ and writers’ strikes,” CEO Ellis Jacob said. “The start of 2024 is bringing with it the much-anticipated Dune: Part Two, Ghostbusters: Frozen Empire, Bob Marley: One Love, pop-culture movie favourite turned musical Mean Girls and international film Fighter.”

At press time, shares of CGX were down 1.5 per cent to $8.13.

Tagged with: cgx
Staff

Recent Posts

Cannara Biotech is a buy, Research Capital says

Research Capital analyst Greg McLeish said in a July 29 update that Cannara Biotech (Cannara Biotech Stock Quote, Chart, News,… [Read More]

15 hours ago

Ahead of Q2 results, is Tantalus Systems a buy?

Beacon Securities analyst Gabriel Leung noted in a July 30 report that Tantalus Systems (Tantalus Systems Holding Stock Quote, Chart,… [Read More]

16 hours ago

Sanuwave Health is a buy, Roth Capital says

Roth Capital Markets is initiating coverage of Sanuwave Health (Sanuwave Health Stock Quote, Chart, News, Analysts, Financials NASDAQ:SNWV) with a… [Read More]

16 hours ago

Shoulder Innovations is an IPO to watch, this analyst says

Roth Capital Markets analyst Jason Wittes noted in a July 28 pre-IPO report that Shoulder Innovations, a new entrant in… [Read More]

16 hours ago

Nextracker wins price target raise at Roth

Roth Capital Markets analyst Philip Shen said in a July 28 earnings preview that Nextracker (Nextracker Stock Quote, Chart, News,… [Read More]

17 hours ago

Telus is my top telecom stock, Brian Madden says

Brian Madden, Chief Investment Officer at First Avenue Investment Counsel, said on BNN Bloomberg’s Market Call on July 25 that… [Read More]

2 days ago